Cubist Pharmaceuticals, Inc. Reports GAAP Diluted Net Income of $0.16 Per Share in Fourth Quarter 2007 and GAAP Diluted Net Income of $0.85 Per Share for Full Year 2007

LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the fourth quarter and year ended December 31, 2007. Total net revenues for the fourth quarter of 2007 increased 52% year over year from $56.5 million in the fourth quarter of 2006 to $85.6 million in the fourth quarter of 2007. This increase was attributable primarily to net sales of CUBICIN® (daptomycin for injection) which increased 51% year over year from $56.4 million in the fourth quarter of 2006 to $85.1 million in the fourth quarter of 2007.